spacer
home > pmps > spring 2018 > dissolvable development
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Dissolvable Development

Today’s orally disintegrating tablet (ODT) formulators have access to several direct compressible excipient platforms especially designed for ODTs. Each of these platforms has its own advantages and disadvantages, such as poor compactibility, slow disintegration, lack of stability, or inferior organoleptic properties. To be successful, future excipient developments should seek to address these key performance attributes of ODTs simultaneously. Functionalised calcium carbonate (FCC) provides a solution that combines good compactibility with fast disintegration time. Therefore, besides being a promising excipient for solid oral dosage forms, it can help to tackle challenges in ODT formulation.

Enhanced Compliance

ODTs and orally disintegrating granules (ODGs) are designed to dissolve in the mouth within seconds without the need for water. Because of their convenience, both dosage forms can enhance compliance, which is a clear advantage for paediatric, geriatric, and psychiatric formulations. Although ODTs and ODGs are mostly used in immediate release formulations, microencapsulation of the API with the appropriate polymers enables other forms of drug delivery. If a closer look is taken at the ideal characteristics of both formulations, it turns out that an optimum speed of disintegration exists. If the water uptake phase of disintegration is too quick, then it is often associated with the drying of the mouth, which may cause patient discomfort. The best sensation for the patient is when the disintegration starts quickly upon contact with a small amount of saliva and lasts no more than 30 seconds. After disintegration, the optimum texture gives the patient a feeling that the tablet has turned into syrup. Insoluble ingredients have to be as small as possible to avoid a sandy feeling in the mouth. A short disintegration time requires specific excipients that differ from those used in other oral dosage forms.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Carolina Diaz Quijano joined Omya International in 2013. She has worked as Senior Scientist for Mineral Surface Chemistry and as Manager for Technical Services and Innovation. Currently, Carolina holds the position of Manager for Innovation and Technical Marketing for pharma and nutraceutical applications. Previously, she has worked as a research collaborator in protein engineering at the University of Zurich, Switzerland, and in diagnostics and genetic profiles at the start-up Stab Vida in Portugal. Carolina earned a PhD in life sciences from ETH Zurich.
spacer
Dr Carolina Diaz Quijano
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Webinar Will Discuss How to Optimize Microbiome Research

BioIVT, a leading provider of research models and services for drug development, today announced that it is hosting a webinar entitled “The Microbiome: Understanding Why Collection and Processing Matters” at 11 a.m. ET on July 25.
More info >>

White Papers

Points to Consider When Developing a TMF (Trial Master File) Strategy

Phlexglobal Ltd

Many organizations are currently outsourcing clinical trial activities to one or more contract research organizations (CROs). This strategy enables companies to leverage specialized expertise and take advantage of flexible resourcing throughout the conduct of a clinical trial. Outsourcing minimizes the costs of recruiting experts, building a team and maintaining an infrastructure. However, it can also add complexity as the organization looks to meets its compliance obligations regarding clinical trial documentation. The documentation referred to in Article 15(5) of Directive 2001/20/EC as the trial master file shall consist of essential documents, which enable both the conduct of a clinical trial and the quality of the data produced to be evaluated.1 This essential study specific documentation is also known as the TMF. As organizations try to minimize their reliance on paper files, the electronic TMF (eTMF) has emerged. A current industry initiative to standardize the organization of this content is known as the TMF Reference Model. This model is helping standardization efforts across paper and electronic systems. As companies implement outsourcing strategies, CROs and sponsor organizations look for a common foundation on which to build their TMF capabilities. The following paper outlines some of the challenges organizations face when outsourcing clinical trial activities to multiple contract research organizations and a strategy to facilitate partnering and management of trial information between sponsors and CROs.
More info >>

 
Industry Events

Drug Discovery 2018

9-10 October 2018, ExCeL Arena, London, UK

ELRIG’s flagship conference, Drug Discovery, has become the largest meeting of life sciences industry professionals in the UK. Now in its 12th year, Drug Discovery 2018 will take place in London’s Excel Arena. This 2-day event will bring together more than 1200 delegates and over 100 exhibiting companies from around the world who will highlight the latest ground-breaking research, discuss cutting-edge advances in the application of laboratory technology to understand disease biology and to identify novel chemical and biological candidate drugs.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement